New antiviral therapies for hepatitis C

Jacqueline O'Leary, Raymond T. Chung

Research output: Contribution to journalReview article

Abstract

Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.

Original languageEnglish (US)
Pages (from-to)235-243
Number of pages9
JournalExpert Review of Anti-Infective Therapy
Volume2
Issue number2
StatePublished - Apr 1 2004

Fingerprint

Hepatitis C
Antiviral Agents
Therapeutics
Life Cycle Stages
Liver Transplantation

Keywords

  • Hepatits C
  • Interferon
  • New therapies

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

New antiviral therapies for hepatitis C. / O'Leary, Jacqueline; Chung, Raymond T.

In: Expert Review of Anti-Infective Therapy, Vol. 2, No. 2, 01.04.2004, p. 235-243.

Research output: Contribution to journalReview article

O'Leary, Jacqueline ; Chung, Raymond T. / New antiviral therapies for hepatitis C. In: Expert Review of Anti-Infective Therapy. 2004 ; Vol. 2, No. 2. pp. 235-243.
@article{f3832baf5821400eaaef412b21fb8e5c,
title = "New antiviral therapies for hepatitis C",
abstract = "Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.",
keywords = "Hepatits C, Interferon, New therapies",
author = "Jacqueline O'Leary and Chung, {Raymond T.}",
year = "2004",
month = "4",
day = "1",
language = "English (US)",
volume = "2",
pages = "235--243",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - New antiviral therapies for hepatitis C

AU - O'Leary, Jacqueline

AU - Chung, Raymond T.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.

AB - Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.

KW - Hepatits C

KW - Interferon

KW - New therapies

UR - http://www.scopus.com/inward/record.url?scp=2942525691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942525691&partnerID=8YFLogxK

M3 - Review article

C2 - 15482189

AN - SCOPUS:2942525691

VL - 2

SP - 235

EP - 243

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 2

ER -